ANL.BO · BSE
Accretion Nutraveda Limited
₹296
+2.78% (+₹8)
Prev. close
₹288
Volume
63,000
As of
17 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Accretion Nutraveda Limited
Accretion Nutraveda Limited manufactures and supplies ayurvedic, nutraceutical, and wellness formulations in India and internationally. The company offers nutraceuticals products, including formulation for brain, memory and neuron care, UTI care, cardiac care, liver care, protein supplement, pediatric care, git care, effervescent, joint and bone care, immunity booster, gynec care, hair, skin, nail care, and infertility and PCOS care. It also provides ayurvedic products for bone and joint, respiratory, gynec, aphrodisiac, skin, digestive, hair, urinary track, systemic, and nasal congestion and pain, care, as well as single herbs and baby products. The company offers its products in tablets, capsule, syrup, sachet, powder, drops, dry syrup, oral spray, oil/ointment, granules, asav-arishta, cream, facewash/scrub, body massage oil, shampoo, gel, gripe water, balm, and inhaler pack forms. In addition, it provides end-to-end solutions, including product development, formulation support, manufacturing, packaging, and private-label services. Accretion Nutraveda Limited was incorporated in 2021 and is headquartered in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mayurbhai Popatlal Sojitra
Headquarters
Ahmedabad
Website
accretionnutraveda.comExchange
View on BSE ↗Key stats
Market cap
₹214.30 Cr
P/E ratio (TTM)
31.7
EPS (TTM)
₹9.35
Shares float
18.43 L
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹2.90 Cr | ₹5.01 Cr | ₹16.00 Cr | ₹33.60 Cr | |
| EBITDA | ₹75.96 L | ₹1.40 Cr | ₹3.65 Cr | ₹7.01 Cr |
| ₹28.06 L | ₹82.19 L | ₹2.50 Cr | ₹5.07 Cr | |
| Diluted EPS | ₹0.39 | ₹1.14 | ₹3.45 | ₹9.35 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹4.06 Cr | ₹4.64 Cr | ₹10.54 Cr | ₹41.78 Cr | |
| ₹1.97 Cr | ₹2.17 Cr | ₹3.86 Cr | ₹4.23 Cr | |
| Stockholders' equity | ₹26.31 L | ₹1.08 Cr | ₹5.05 Cr | ₹35.47 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹68.13 L | ₹23.02 L | ₹-2.22 Cr | ₹-9.42 Cr | |
| Investing cash flow | ₹-55,000 | ₹-15.83 L | ₹-87.20 L | ₹-14.50 Cr |
| ₹-63.40 L | ₹-3.91 L | ₹2.98 Cr | ₹25.19 Cr | |
| Capital expenditure | ₹-55,000 | ₹-15.83 L | ₹-87.20 L | ₹-6.03 Cr |
| End cash position | ₹8.61 L | ₹11.90 L | ₹1.54 L | ₹1.28 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Accretion Nutraveda Limited | ₹214.30 Cr | ₹296 | 31.6 | 6.04 | 14.3% | 0.12 | +110.0% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Accretion Nutraveda Ltd Financials – Balance Sheet, Profit & Loss, Cash Flow
Value Research · 22 days ago